Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away? Zacks Equity Research - Zacks Investment Research - Thu Jan 10, 7:43AM CST Zacks Equity Research - ZACKS - Thu Jan 10, 7:43AM CST
Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Champions Oncology Participates in Pre-Clinical Studies to Identify Novel Therapy for Childhood Cancer ACCESSWIRE - Mon Dec 17, 3:30PM CST CMTX - Mon Dec 17, 3:30PM CST
HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development...
Champions Oncology Reports Quarterly Revenue of $6.7 Million ACCESSWIRE - Mon Dec 17, 3:00PM CST CMTX - Mon Dec 17, 3:00PM CST
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018 PR Newswire - Mon Dec 10, 3:30PM CST CMTX - Mon Dec 10, 3:30PM CST
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced...
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know Zacks Equity Research - Zacks Investment Research - Thu Nov 22, 4:45PM CST Zacks Equity Research - ZACKS - Thu Nov 22, 4:45PM CST
In the latest trading session, Champions Oncology (CSBR) closed at $10.39, marking a +0.39% move from the previous day.
Champions Oncology (CSBR) Stock Sinks As Market Gains: What You Should Know Zacks Equity Research - Zacks Investment Research - Fri Nov 16, 4:45PM CST Zacks Equity Research - ZACKS - Fri Nov 16, 4:45PM CST
Champions Oncology (CSBR) closed the most recent trading day at $12.41, moving -1.43% from the previous trading session.
Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers PR Newswire - Thu Nov 15, 10:00AM CST CMTX - Thu Nov 15, 10:00AM CST
The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help...
Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference PR Newswire - Wed Nov 7, 7:30AM CST CMTX - Wed Nov 7, 7:30AM CST
Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced...
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know Zacks Equity Research - Zacks Investment Research - Mon Nov 5, 4:45PM CST Zacks Equity Research - ZACKS - Mon Nov 5, 4:45PM CST
Champions Oncology (CSBR) closed at $13.43 in the latest trading session, marking a +1.13% move from the prior day.
Champions Oncology Sees Hammer Chart Pattern: Time to Buy? Zacks Equity Research - Zacks Investment Research - Fri Nov 2, 6:27AM CDT Zacks Equity Research - ZACKS - Fri Nov 2, 6:27AM CDT
Champions Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Mon Oct 29, 8:30AM CDT Zacks Equity Research - ZACKS - Mon Oct 29, 8:30AM CDT
Is (CSBR) Outperforming Other Medical Stocks This Year?
Champions Oncology (CSBR) Gains As Market Dips: What You Should Know Zacks Equity Research - Zacks Investment Research - Tue Oct 23, 4:45PM CDT Zacks Equity Research - ZACKS - Tue Oct 23, 4:45PM CDT
Champions Oncology (CSBR) closed at $12.21 in the latest trading session, marking a +0.58% move from the prior day.
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Fri Oct 12, 8:30AM CDT Zacks Equity Research - ZACKS - Fri Oct 12, 8:30AM CDT
Is (CSBR) Outperforming Other Medical Stocks This Year?
Affimed Down After Clinical Hold on Two Early-Stage Studies Zacks Equity Research - Zacks Investment Research - Tue Oct 9, 9:01AM CDT Zacks Equity Research - ZACKS - Tue Oct 9, 9:01AM CDT
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th PR Newswire - Thu May 3, 7:30AM CDT CMTX - Thu May 3, 7:30AM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management...
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House PR Newswire - Wed Apr 4, 7:30AM CDT CMTX - Wed Apr 4, 7:30AM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management...
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes ACCESSWIRE - Wed Mar 28, 8:02AM CDT CMTX - Wed Mar 28, 8:02AM CDT
Stock Monitor: Champions Oncology Post Earnings Reporting
Champions Oncology, Inc. to Host Earnings Call ACCESSWIRE - Thu Mar 15, 3:09PM CDT CMTX - Thu Mar 15, 3:09PM CDT
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR) will be discussing their earnings results in their Q3 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern...
Champions Oncology Reports Quarterly Revenue of $5.1 Million PR Newswire - Thu Mar 15, 3:01PM CDT CMTX - Thu Mar 15, 3:01PM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial...
